HCP SMA News Today – The Web's Leading Resource For People …
WEBZolgensma alone helps children with SMA type 1: Real-world study. The gene therapy Zolgensma (onasemnogene abeparvovec-xioi), given as a sole treatment, improves motor skills and preserves lung health and feeding abilities in infants with spinal muscular atrophy (SMA) type 1, according to a real-world study.
SMA News Today Home | SMA News Today
WEBSep 18, 2024 · Standardized SMA newborn screening may aid early treatment. Substantial differences in newborn screening (NBS) practices for spinal muscular atrophy (SMA) across the U.S. could impact referral patterns or the timing …
Spinal Muscular Atrophy: Nutrition and Supplementation
WEBThe nutritional management of patients with progressive neuromuscular diseases like Spinal Muscular Atrophy (SMA) is complex and is achieved optimally with an individualized approach from a multidisciplinary care team. 1,2 Patients with SMA need nutritional monitoring at least annually with assessment of caloric intake and standard anthropomorphic measurements. 3 In younger children, a ...
FAQs About Evrysdi (Risdiplam) - SMA News Today
WEBAug 7, 2020 · Evrysdi is an oral liquid treatment that works by modifying SMN2 splicing, like Spinraza, to increase SMN protein production in SMA. Learn how to take Evrysdi, its cost, availability, and how it differs from Spinraza in this article.
Spinal Muscular Atrophy: Cardiac Disease – HCP SMA News Today
WEBLearn how SMA affects the heart and increases the risk of congenital heart defects, ECG abnormalities and cardiac fibrosis. Find out the types of SMA and their association with cardiac pathology and the number of SMN2 gene copies.
SMA Type 2: Symptoms, Treatment, and More - SMA News Today
WEBFeb 2, 2023 · SMA type 2 is a rare genetic disease that causes muscle weakness and wasting in infancy. Learn about the symptoms, diagnosis, treatment options, and life expectancy of this intermediate form of spinal muscular atrophy.
Spinal muscular atrophy diagnosis and testing - SMA News Today
WEBJan 20, 2023 · Due to the progressive nature of spinal muscular atrophy (SMA) — a rare genetic disease caused by the progressive loss of motor neurons, the specialized nerve cells that control voluntary movements — an early diagnosis is critical. People living with SMA who receive a timely diagnosis can start receiving treatment immediately.
FDA Approves Evrysdi, First Oral Treatment for All SMA Types
WEBAug 7, 2020 · Evrysdi is the first oral treatment for all SMA types, approved by the FDA in August 2020. Its list price is $340,000 a year, but patients can get financial assistance and insurance support. Learn more about its effectiveness, safety, and systemic distribution.
Spinal Muscular Atrophy: Electromyography - SMA News Today
WEBSpinal Muscular Atrophy (SMA) is a progressive neuromuscular disease associated with typically proximal muscle weakness and atrophy due to degeneration of the anterior horn cells of the spinal cord. 1 Prior to genetic testing as the gold standard diagnostic method for SMA, electromyography (EMG) was used widely to diagnose SMA. 2,3 EMG still has a role in the diagnostic confirmation of motor ...
Branaplam – HCP SMA News Today
WEB8. Palacino J, Swalley SE, Song C, et al. SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice. Nat Chem Biol. Jul 2015;11(7):511-517. 9. Charnas L, Voltz E, Pfister C, et al. Safety and efficacy findings in the first-in-human trial (FIH) of the oral splice modulator branaplam in type 1 spinal muscular atrophy (SMA): interim results.